Rates of malignancy associated with juvenile idiopathic arthritis and its treatment

T Beukelman, K Haynes, JR Curtis, F Xie… - Arthritis & …, 2012 - Wiley Online Library
Objective To determine the relative rates of incident malignancy among children with
juvenile idiopathic arthritis (JIA) with respect to treatment as compared to children without …

Autoimmunity and cancer

R Masetti, A Tiri, A Tignanelli, E Turrini… - Autoimmunity …, 2021 - Elsevier
In many autoimmune rheumatic diseases, there is an increased risk of cancer compared to
the general population. The link between autoimmunity and cancer is dynamic and …

Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and …

J Swart, G Giancane, G Horneff, B Magnusson… - Arthritis research & …, 2018 - Springer
Background The availability of methotrexate and the introduction of multiple biological
agents have revolutionized the treatment of juvenile idiopathic arthritis (JIA). Several …

[HTML][HTML] Biologics in juvenile idiopathic arthritis-main advantages and major challenges: A narrative review

A Adrovic, M Yildiz, O Köker, S Şahin… - Archives of …, 2021 - ncbi.nlm.nih.gov
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. The
disease is divided in different subtypes based on main clinical features and disease course …

Advances from clinical trials in juvenile idiopathic arthritis

DJ Lovell, N Ruperto, EH Giannini… - Nature Reviews …, 2013 - nature.com
Treatments available to children with juvenile idiopathic arthritis (JIA) have improved
dramatically in the past 15 years, largely because of the development of powerful new …

Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis

VC Kok, JT Horng, JL Huang, KW Yeh, JJ Gau… - BMC cancer, 2014 - Springer
Background To investigate the association and magnitude of risk between JIA, its associated
treatment and cancer development in Taiwanese children. Methods Nationwide population …

What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?

JF Swart, S de Roock, NM Wulffraat - Arthritis Research & Therapy, 2013 - Springer
This review summarizes the immunological consequences of biological therapies used in
juvenile idiopathic arthritis (JIA). For every frequently used biological agent the …

Juvenile idiopathic arthritis and malignancy

N Ruperto, A Martini - Rheumatology, 2014 - academic.oup.com
Biologic agents represent a major advance in the treatment of JIA. In 2008 a US Food and
Drug Administration (FDA) warning raised the hypothesis that anti-TNF therapies may be …

[HTML][HTML] The risk of cancer in pediatric-onset immune-mediated inflammatory diseases–A nationwide study

A Ehrström, S Jansson, MH Jørgensen, V Wewer… - Journal of …, 2024 - Elsevier
Background and objectives Adult-onset immune-mediated inflammatory disease (IMID)
increases the risk of several cancers. However, data on pediatric-onset IMID (pIMID) …

Juvenile idiopathic arthritis: management and therapeutic options

NM Ruth, MH Passo - Therapeutic advances in …, 2012 - journals.sagepub.com
The goals of treatment for juvenile idiopathic arthritis (JIA) include: suppression of
inflammation, achievement of remission, relief of pain, maintenance of function and doing so …